Progress on the impurities in Oxaliplatin

NIU Chong; LIU Gui-hua; ZHANG Zhong-hu

doi:10.3969/j.issn.1006-0111.2012.06.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

The research progress on the preparation and impurities of Oxaliplatin were summarized based on the recent documents, which generalize the impurity organization, impurity controlling and preparation stability. The principal impurities in Oxaliplatin were oxalic acid, impurity B, impurity C, impurity D and impurity E. All of the impurities were produced during the syntheses and also could be degraded from Oxaliplatin and its preparation. The impurities in Oxaliplatin and its preparation must be controlled respectively to ensure the security and effect of the drugs.

Progress on the impurities in Oxaliplatin

1. Shandong Institute for Food and Drug Control, Jinan 250101, China

2. Shandong Ruizhong Medicine Co. LTD, Jining 272000, China

Received Date: 2011-09-09

Rev Recd Date: 2012-05-09

Key words:

Abstract: The research progress on the preparation and impurities of Oxaliplatin were summarized based on the recent documents, which generalize the impurity organization, impurity controlling and preparation stability. The principal impurities in Oxaliplatin were oxalic acid, impurity B, impurity C, impurity D and impurity E. All of the impurities were produced during the syntheses and also could be degraded from Oxaliplatin and its preparation. The impurities in Oxaliplatin and its preparation must be controlled respectively to ensure the security and effect of the drugs.

HTML

Reference (25)

[1]	Erndest W, Christen MG.Current status of platinum-based antitumor Drugs[J]. Chem Rev, 1999, 99:2451.
[2]	Yoshinori K, Kenji I. Cis-platinum(Ⅱ) complex of trans-L-1,2-diaminocyclo-hexane[P]. USA. 4169846. 1979-08-02.
[3]	Koji O, Yuko H, Chihiro N. Platinum compound and process of preparing same[P].USA. US5290961. 1994-03-01.
[4]	Frantiske Z, Anna CP. Oxaliplatin with a low content of accompanying impurities and a method for preparetion thereof[P]. USA. 7351846B2. 2008-04-01.
[5]	Kidani Y. Oxaliplatin[J]. Drugs of the Future, 1989, 14(6):529.
[6]	何健,刘伟平,李永年,等. 抗癌药奥沙利铂的一种新合成工艺[P].中国专利. CN1837223A. 2006-09-27.
[7]	黄毅岚,张丹. HPLC法测定奥沙利铂有关物质的含量[J]. 中国药房,2008,19(1):50.
[8]	傅萍,兰婉玲,张蕾. 关于注射用奥沙利铂有关物质检查方法的探讨[J].药物分析杂志,2009,29(1):1850.
[9]	马艺,王鑫. 草酸铂周围神经毒性机制研究进展[J].国外医学肿瘤学分册,2005,32(3):234.
[10]	Lara MP, Mario RD, Elena R, et al. Oxaliplatin-related neurotoxicity:How and Why?[J]. Oncology Hematology, 2006,59:159.
[11]	刘颖,赵俊,张爽,等. 高效液相色谱法测定注射用奥沙利铂中草酸的含量[J]. 药物分析杂志, 2007,27(10):1565.
[12]	刘祝东,栾春芳,普绍平. 奥沙利铂及其手性异构体的高效液相色谱分析[J]. 贵金属,2007,28(2),49.
[13]	Chris HT, Martin AG, Graham L, et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function[J]. Clic Cancer Res, 2007, 13(16):4832.
[14]	Nicholas H, Ross B, Stephen B, et al. Oxaliplatin formulations[P]. USA. US 6306902 B1. 2001-10-23.
[15]	Houssam I, Rolland YM. Pharmacertically stable preparetion of oxaliplatinum[P]. USA. 5716988A.1998-02-10.
[16]	Sara L, Alessandro M, Cristina C. Platinum Derivative Pharmacertical Formulations[P]. USA. US6476048. 2002-11-05.
[17]	Andre A, Cisternino A, Roy AL, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection[J]. Am J Health Syst Pharm, 2007, 64:1950.
[18]	Audrey J, Sandrine R, Marie CD, et al. Stability of oxaliplatin solution[J]. The Annals of Pharmacotherapy, 2009, 43:390.
[19]	Satish CU, Manoj K, Ajeet KS, et al. Stable oxaliplatin formulation[P]. USA. US2007/0054957A1. 2007-03-08.
[20]	Schridde E, Merbach BD. Concentrated solution of oxaliplatinum[P]. Europe. EP1466599.2004-10-13.
[21]	Sara L, Alessandro M, Crestina C. Pharmaceutical formulation of a platium derivative[P]. USA. US2003/0109515 A1. 2003-06-12.
[22]	Darryl VW, Aikun L. Oxaliplatin Formulations[P]. USA. US2005/0090544 A1. 2005-03-08.
[23]	Darryl VW, Aikun L. Oxaliplatin Formulations[P]. USA.US2007/0155833 A1. 2007-04-05.
[24]	Ibrahim H, Bayssas M. Pharmaceutical stable oxaliplatium preparation for parenteral administration[P]. Europe. EP1207875B1. 2002-05-29.
[25]	Michaela R, Katrin W. Plastic bottle for oxaliplatin solution[P]. USA. US2008/0208141 A1. 2008-8-28.

Message Board

Progress on the impurities in Oxaliplatin

doi: 10.3969/j.issn.1006-0111.2012.06.004

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views